Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare RUXOLITINIB (OPZELURA) and Tofacitinib (Xeljanz) — clinical data, side effects, and patient experiences.
OPZELURA, Jakafi, Opzelura · JAK Inhibitor
How it works
12.1 Mechanism of Action Ruxolitinib, a Janus kinase (JAK) inhibitor, inhibits JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are import...
Approved for
Xeljanz · JAK Inhibitor
How it works
Inhibits Janus kinases JAK1 and JAK3, modulating the signalling of interleukins and interferons involved in immune and inflammatory pathways.
Approved for
Estimated frequency (%) based on clinical trial data
No head-to-head clinical studies found for RUXOLITINIB vs Tofacitinib.
Both RUXOLITINIB and Tofacitinib belong to the JAK Inhibitor class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. RUXOLITINIB is administered via Topical, whereas Tofacitinib uses Oral. Route of administration can affect onset of action and patient adherence.
RUXOLITINIB carries 4 FDA warnings. Tofacitinib carries 2 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.